RCS - OptiBiotix Health - Distribution agreement for SlimBiome

OptiBiotix HealthAnnouncement

28/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231128:nRSb8179Ua&default-theme=true

RNS Number : 8179U  OptiBiotix Health PLC  28 November 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Distribution agreement with Ravenswood for SlimBiome®

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces it has signed an agreement with Ravenswood Ingredients Pty Ltd
("Ravenswood") for the distribution of SlimBiome® in Australia and New
Zealand.

 

Ravenswood is part of the Brenntag group, a specialised ingredient supplier
with more than 17,000 employees in over 72 countries, and revenues of
€19.4bn in 2022. Brenntag group acquired Ravenswood in November 2022 as part
of its nutrition strategy which focuses on specialised value-added
ingredients. See: Brenntag strengthens its position in Specialties in
Australia and New Zealand by acquiring the Life Science business from
Ravenswood | Brenntag
(https://www.brenntag.com/en-nz/media/news/brenntag-strengthens-its-position-in-specialties-in-australia-and-new-zealand-by-acquiring-the-life-science-business-from-ravenswood.html)
.

 

Ravenswood brings access to the food and beverage markets and will complement
existing partner capabilities which are largely focused on the meal
replacement market to broaden OptiBiotix's impact in Australia and New
Zealand. This is part of a strategy of building partnerships to support
expansion of OptiBiotix's geographical footprint with companies who bring
national and international capability for highly differentiated value-added
ingredients in high growth markets around the world.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this
agreement with Ravenswood who bring specialised food ingredient expertise as
part of the Brenntag group, a global market leader in chemicals and
ingredients distribution. This agreement is another example of OptiBiotix
working with large partners and extends access to the food and beverage
markets within Australia and New Zealand with a company which is part of a
group which is a global leader in the ingredients market."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                        www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Peterhouse Capital Limited (Broker)          Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                              Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFEMFWWEDSEEF